Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Exagen Inc.NASDAQ: XGN
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items dips below year-ago levels
Q1 FY2026 other non-cash items of $69K fell 80.3% year over year, behind the +164.1% change in trailing-twelve-month other non-cash items. Over 3 fiscal years it compounded at -19.1% a year.
Context
- Other non-cash items amounted to 6.1% of revenue in FY2025, up 3.5 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -80.3% toward the trailing-twelve-month pace of +164.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 4.03M USD
- Year-over-year change
- +182.9%
- 4-year CAGR
- +48.9%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.03M | +182.9% |
| FY2024 | 2024-12-31 | 1.43M | -54.3% |
| FY2023 | 2023-12-31 | 3.12M | -59.1% |
| FY2022 | 2022-12-31 | 7.62M | +830.2% |
| FY2021 | 2021-12-31 | 819K | — |
Other Non-Cash Items vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 other non-cash items of $3.75M is the 6th largest of the 11 companies compared; the peer median is $3.37M.
- Its year-over-year change of +164.1% is the 3rd highest of 10, against a peer median of -46.8%.
- Other non-cash items amounts to 5.5% of revenue for XGN, versus a peer median of 7.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.41M | — | -33.1% | 25.5% | |
| LTM Jun 2026 | $20.05M | -31.3% | +4.3% | 2.6% | |
| LTM Mar 2026 | $8.5M | +294.7% | +47.8% | 7.9% | |
| FY2025 | $8.37M | -3025.5% | +169.2% | 7.8% | |
| LTM Mar 2026 | $4.76M | -94.7% | -21.2% | 56.9% | |
| LTM Mar 2026 | $3.75M | +164.1% | -19.1% | 5.5% | |
| LTM Mar 2026 | $3.74M | +252.3% | — | 1.7% | |
| LTM Mar 2026 | $3.01M | -46.8% | -59.7% | 7.2% | |
| LTM Mar 2026 | $2.42M | +4.8% | — | 7.8% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $1.33M | -650.6% | — | 12.9% |
| LTM Mar 2026 | $834K | -92.4% | -11.7% | 1.0% | |
| Peer median (excluding XGN) | $3.37M | -46.8% | -11.7% | 7.8% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| Deferred Income Tax | 148K | (306K) | 0 | 0 | 0 |
| Stock-Based Compensation | 4.73M | 4.7M | 3.62M | 1.76M | 2.16M |
| Change in Working Capital | (61K) | 1.67M | 325K | (3.08M) | (1.98M) |
| Accounts Receivables | (744K) | 3.58M | (474K) | (1.28M) | (3.02M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (655K) | 901K | 67K | 308K | 42K |
| Other Working Capital | 1.34M | (2.81M) | 732K | (2.1M) | 997K |
| Other Non-Cash Items | 819K | 7.62M | 3.12M | 1.43M | 4.03M |
| Operating Cash Flow | (20.27M) | (32.14M) | (14.46M) | (13.28M) | (13.63M) |
| Capital Expenditures | (2.37M) | (4.32M) | (828K) | (515K) | (641K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 15K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (50K) | 0 | 24K | 0 | 0 |
| Investing Cash Flow | (2.42M) | (4.32M) | (804K) | (515K) | (626K) |
| Debt Repayment | (525K) | (696K) | (10.94M) | (861K) | 2.01M |
| Common Stock Issued | 69.14M | 446K | 306K | 198K | 22.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.94M) | (239K) | 0 | 0 | 0 |
| Financing Cash Flow | 64.68M | (489K) | (10.63M) | (663K) | 24.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.99M | (36.95M) | (25.9M) | (14.46M) | 10.18M |
| Free Cash Flow | (22.64M) | (36.46M) | (15.29M) | (13.79M) | (14.27M) |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.